Deter sophisticated counterfeiting and restore consumer trust
The pharmaceutical industry faces significant challenges from counterfeiting, which severely undermines patient safety, erodes brand trust, disrupts supply chains, and causes billions in economic losses per year.
But companies also face growing risks when it comes to their digital footprint. Preventing internal leaks of intellectual property and sensitive information is critical, for example, and yet unauthorized dissemination of internal information is only one screen grab or photograph away.
Digimarc’s anti-counterfeiting solutions enhance security, streamline consumer and field agent verification, enhance compliance, and even help you facilitate better recycling. Our suite of digitally-connected authentication products can complement existing security protections or work stand-alone, providing seamless, deterministic identification using a mobile device—no app required.
Digimarc also has solutions to protect pharmaceutical companies’ digital footprint, guarding confidential information against insider and trusted-counterparty leaks, reducing the cost of compliance with internal digital asset policies, and defending against unauthorized use or re-use no matter where your digital assets travel online.
Of medications worldwide are either subpar or fake, according to the WHO
Tackling Counterfeit Drugs: The Challenges and Possibilities - PMC
In counterfeit drugs sold annually, according to the WHO
Of security breaches in pharma and biotech stem from insiders
Digimarc can help you:
Empower consumers to verify product authenticity instantly, with the option to connect them to online content or assistance when products don’t authenticate –no app required.
Enable brand inspectors to quickly detect and report fakes using secure apps.
Allow customer support and back-office brand protection teams to remotely authenticate products based on customer queries.
Understand and analyze counterfeit product trends, gray markets, and events for more targeted defense.
Protect confidential internal information from insider leaks and combat the risk of limited-distribution content being disseminated without authorization.
Reduce the cost and complexity of ensuring compliance with internal digital asset policies.